

# Serena Spudich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/493975/publications.pdf>

Version: 2024-02-01

113  
papers

8,469  
citations

57719

44  
h-index

48277

88  
g-index

115  
all docs

115  
docs citations

115  
times ranked

9731  
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating vascular diseases in people living with HIV by nuclear imaging. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 1576-1582.	1.4	1
2	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 493-502.	2.9	15
3	Nervous system consequences of COVID-19. <i>Science</i> , 2022, 375, 267-269.	6.0	242
4	Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T <sup>H</sup> 1 cell clones. <i>Immunity</i> , 2022, 55, 1013-1031.e7.	6.6	61
5	HIV Compartmentalization in the CNS and Its Impact in Treatment Outcomes and Cure Strategies. <i>Current HIV/AIDS Reports</i> , 2022, 19, 207-216.	1.1	6
6	HIV viral transcription and immune perturbations in the CNS of people with HIV despite ART. <i>JCI Insight</i> , 2022, 7, .	2.3	17
7	Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e1885-e1892.	2.9	8
8	Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients. <i>JAMA Neurology</i> , 2021, 78, 41.	4.5	124
9	Cognitive trajectories after treatment in acute HIV infection. <i>Aids</i> , 2021, 35, 883-888.	1.0	13
10	Neuropathogenesis of acute coronavirus disease 2019. <i>Current Opinion in Neurology</i> , 2021, 34, 417-422.	1.8	14
11	Preliminary In Vivo Evidence of Reduced Synaptic Density in Human Immunodeficiency Virus (HIV) Despite Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2021, 73, 1404-1411.	2.9	25
12	Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. <i>Cell Reports Medicine</i> , 2021, 2, 100288.	3.3	121
13	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. <i>PLoS ONE</i> , 2021, 16, e0250987.	1.1	30
14	VZV myelitis with secondary HIV CSF escape. <i>BMJ Case Reports</i> , 2021, 14, e241738.	0.2	1
15	Ischemic Stroke, Inflammation, and Endotheliopathy in COVID-19 Patients. <i>Stroke</i> , 2021, 52, e233-e238.	1.0	31
16	Abrupt and altered cell-type specific DNA methylation profiles in blood during acute HIV infection persists despite prompt initiation of ART. <i>PLoS Pathogens</i> , 2021, 17, e1009785.	2.1	12
17	Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?. <i>Current Opinion in Psychiatry</i> , 2021, 34, 177-185.	3.1	26
18	Prior Stroke and Age Predict Acute Ischemic Stroke Among Hospitalized COVID-19 Patients: A Derivation and Validation Study. <i>Frontiers in Neurology</i> , 2021, 12, 741044.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Minimal detection of cerebrospinal fluid escape after initiation of antiretroviral therapy in acute HIV-1 infection. <i>Aids</i> , 2021, 35, 777-782.	1.0	8
20	Cerebrospinal fluid CD4+ T cell infection in humans and macaques during acute HIV-1 and SHIV infection. <i>PLoS Pathogens</i> , 2021, 17, e1010105.	2.1	9
21	Regional brain volumetric changes despite 2 years of treatment initiated during acute HIV infection. <i>Aids</i> , 2020, 34, 415-426.	1.0	21
22	A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection. <i>Journal of Virus Eradication</i> , 2020, 6, 100004.	0.3	23
23	Stroke Code Presentations, Interventions, and Outcomes Before and During the COVID-19 Pandemic. <i>Stroke</i> , 2020, 51, 2664-2673.	1.0	81
24	Determinants of suboptimal CD4 + T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection. <i>Journal of the International AIDS Society</i> , 2020, 23, e25585.	1.2	13
25	Lessons from a neurology consult service for patients with COVID-19. <i>Lancet Neurology</i> , The, 2020, 19, 806-807.	4.9	4
26	Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	75
27	Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019. <i>JAMA Neurology</i> , 2020, 77, 1018.	4.5	748
28	Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. <i>BMC Neurology</i> , 2020, 20, 248.	0.8	108
29	Cognitive disorders in people living with HIV. <i>Lancet HIV</i> , the, 2020, 7, e504-e513.	2.1	78
30	Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. <i>Journal of the International AIDS Society</i> , 2020, 23, e25444.	1.2	7
31	Resting-state neural signatures of depressive symptoms in acute HIV. <i>Journal of NeuroVirology</i> , 2020, 26, 226-240.	1.0	6
32	Switch to dolutegravir is well tolerated in Thais with HIV infection. <i>Journal of the International AIDS Society</i> , 2019, 22, e25324.	1.2	11
33	Treatment of Central Nervous System Manifestations of HIV in the Current Era. <i>Seminars in Neurology</i> , 2019, 39, 391-398.	0.5	8
34	Deep Sequencing Reveals Central Nervous System Compartmentalization in Multiple Transmitted/Founder Virus Acute HIV-1 Infection. <i>Cells</i> , 2019, 8, 902.	1.8	15
35	Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma. <i>Journal of Infectious Diseases</i> , 2019, 220, 1885-1891.	1.9	42
36	Predicting Efavirenz Concentrations in the Brain Tissue of HIV-1 Infected Individuals and Exploring their Relationship to Neurocognitive Impairment. <i>Clinical and Translational Science</i> , 2019, 12, 302-311.	1.5	5

#	ARTICLE	IF	CITATIONS
37	Slowly progressive fatal PML-IRIS following antiretroviral initiation at CD4+ nadir of 350 cells/mm <sup>3</sup> despite CD4+ cell count rise to 900 cells/mm <sup>3</sup> . <i>International Journal of STD and AIDS</i> , 2019, 30, 810-813.	0.5	0
38	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	2.1	139
39	Trajectory Analysis of Cognitive Outcomes in Children With Perinatal HIV. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1038-1044.	1.1	7
40	Neurosyphilis During Acute HIV Infection: A CNS Immunologic and Virologic Characterization. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, e34-e37.	0.9	0
41	HIV persistence in the central nervous system during antiretroviral therapy. <i>Aids</i> , 2019, 33, S103-S106.	1.0	5
42	Exosomal MicroRNAs Associate With Neuropsychological Performance in Individuals With HIV Infection on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 514-522.	0.9	15
43	Defining cerebrospinal fluid HIV RNA escape. <i>Aids</i> , 2019, 33, S107-S111.	1.0	40
44	Potential for early antiretroviral therapy to reduce central nervous system HIV-1 persistence. <i>Aids</i> , 2019, 33, S135-S144.	1.0	13
45	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , 2019, 69, 1345-1352.	2.9	58
46	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. <i>Current HIV/AIDS Reports</i> , 2019, 16, 76-81.	1.1	9
47	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e512.	3.1	50
48	Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance. <i>Journal of Clinical Investigation</i> , 2019, 129, 3339-3346.	3.9	81
49	Acute Retroviral Syndrome Is Associated With High Viral Burden, CD4 Depletion, and Immune Activation in Systemic and Tissue Compartments. <i>Clinical Infectious Diseases</i> , 2018, 66, 1540-1549.	2.9	32
50	Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?. <i>Journal of Infectious Diseases</i> , 2018, 217, 1024-1032.	1.9	29
51	Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary Human Immunodeficiency Virus Infection. <i>Clinical Infectious Diseases</i> , 2018, 67, 1697-1704.	2.9	67
52	Central Nervous System Inflammation and Infection during Early, Nonaccelerated Simian-Human Immunodeficiency Virus Infection in Rhesus Macaques. <i>Journal of Virology</i> , 2018, 92, .	1.5	33
53	Safety of lumbar puncture procedure in an international research setting during acute HIV infection. <i>Journal of Virus Eradication</i> , 2018, 4, 16-20.	0.3	7
54	Residency Training: Progressive gait difficulty and incontinence in a 40-year-old man with HIV. <i>Neurology</i> , 2018, 91, 1065-1070.	1.5	0

#	ARTICLE	IF	CITATIONS
55	Global Health Neurology: HIV/AIDS. <i>Seminars in Neurology</i> , 2018, 38, 238-246.	0.5	4
56	Distribution of Human Immunodeficiency Virus (HIV) Ribonucleic Acid in Cerebrospinal Fluid and Blood Is Linked to CD4/CD8 Ratio During Acute HIV. <i>Journal of Infectious Diseases</i> , 2018, 218, 937-945.	1.9	15
57	Structural and functional brain imaging in acute HIV. <i>NeuroImage: Clinical</i> , 2018, 20, 327-335.	1.4	34
58	Normalization of Soluble CD163 Levels After Institution of Antiretroviral Therapy During Acute HIV Infection Tracks with Fewer Neurological Abnormalities. <i>Journal of Infectious Diseases</i> , 2018, 218, 1453-1463.	1.9	28
59	Depression and Anxiety are Common in Acute HIV Infection and Associate with Plasma Immune Activation. <i>AIDS and Behavior</i> , 2017, 21, 3238-3246.	1.4	43
60	An explanatory factor analysis of a brief self-report scale to detect neurocognitive impairment among HIV-positive men who have sex with men and transgender women in Peru. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1297-1301.	0.6	2
61	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 761-770.	1.5	114
62	High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 108-117.	0.9	31
63	Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 215, 1132-1140.	1.9	50
64	Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. <i>Aids</i> , 2017, 31, 247-252.	1.0	21
65	Neurological Complications of HIV Infection. <i>Current Infectious Disease Reports</i> , 2017, 19, 50.	1.3	50
66	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.3	73
67	Past Substance Use Affects Central Nervous System (CNS) Inflammation in Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
68	Cognitive Impairment and Persistent CNS Injury in Treated HIV. <i>Current HIV/AIDS Reports</i> , 2016, 13, 209-217.	1.1	29
69	HIV-Associated Neurologic Disorders and Central Nervous System Opportunistic Infections in HIV. <i>Seminars in Neurology</i> , 2016, 36, 373-381.	0.5	29
70	Neurologic signs and symptoms frequently manifest in acute HIV infection. <i>Neurology</i> , 2016, 87, 148-154.	1.5	59
71	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. <i>EBioMedicine</i> , 2016, 3, 135-140.	2.7	360
72	Virological and immunological characteristics of HIV-infected individuals at the earliest stage of infection. <i>Journal of Virus Eradication</i> , 2016, 2, 43-48.	0.3	45

#	ARTICLE	IF	CITATIONS
73	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. Journal of Virus Eradication, 2016, 2, 243-250.	0.3	22
74	Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 393-399.	0.9	42
75	Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection. Journal of Infectious Diseases, 2015, 212, 1759-1767.	1.9	34
76	Neuropathogenesis of HIV: From Initial Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND). Current HIV/AIDS Reports, 2015, 12, 16-24.	1.1	150
77	Compartmentalized Replication of R5 T Cell-Tropic HIV-1 in the Central Nervous System Early in the Course of Infection. PLoS Pathogens, 2015, 11, e1004720.	2.1	147
78	Cerebral white matter integrity during primary HIV infection. Aids, 2015, 29, 433-442.	1.0	59
79	Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal of Virology, 2015, 89, 11294-11311.	1.5	54
80	CNS reservoirs for HIV: implications for eradication. Journal of Virus Eradication, 2015, 1, 67-71.	0.3	54
81	641Acute Retroviral Syndrome is Associated with Gut Mucosal CD4 Depletion, Inflammation and High Viral and Proviral Burden in Systemic and Tissue Compartments. Open Forum Infectious Diseases, 2014, 1, S32-S32.	0.4	0
82	HIV and other Retroviral Infections of the Nervous System. , 2014, , 885-909.		0
83	HIV Neurology. Seminars in Neurology, 2014, 34, 005-006.	0.5	2
84	Evolving Character of Chronic Central Nervous System HIV Infection. Seminars in Neurology, 2014, 34, 007-013.	0.5	29
85	Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. Journal of Neuroinflammation, 2014, 11, 199.	3.1	33
86	Peripheral Neuropathy in Primary HIV Infection Associates With Systemic and Central Nervous System Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 303-310.	0.9	34
87	An Example of Genetically Distinct HIV Type 1 Variants in Cerebrospinal Fluid and Plasma During Suppressive Therapy. Journal of Infectious Diseases, 2014, 209, 1618-1622.	1.9	47
88	Longitudinal Characterization of Depression and Mood States Beginning in Primary HIV Infection. AIDS and Behavior, 2014, 18, 1124-1132.	1.4	28
89	Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection. Neurology, 2014, 83, 1592-1600.	1.5	70
90	Treatment of HIV in the CNS: Effects of Antiretroviral Therapy and the Promise of Non-Antiretroviral Therapeutics. Current HIV/AIDS Reports, 2014, 11, 353-362.	1.1	11

#	ARTICLE	IF	CITATIONS
91	Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. <i>Journal of Neuroinflammation</i> , 2013, 10, 62.	3.1	55
92	HIV and Neurocognitive Dysfunction. <i>Current HIV/AIDS Reports</i> , 2013, 10, 235-243.	1.1	60
93	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1147-1158.	2.1	37
94	Cerebrospinal Fluid and Neuroimaging Biomarker Abnormalities Suggest Early Neurological Injury in a Subset of Individuals During Primary HIV Infection. <i>Journal of Infectious Diseases</i> , 2013, 207, 1703-1712.	1.9	142
95	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. <i>Aids</i> , 2012, 26, 1765-1774.	1.0	212
96	Central Nervous System Viral Invasion and Inflammation During Acute HIV Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 275-282.	1.9	434
97	HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a007120-a007120.	2.9	180
98	Change in Brain Magnetic Resonance Spectroscopy after Treatment during Acute HIV Infection. <i>PLoS ONE</i> , 2012, 7, e49272.	1.1	99
99	HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types. <i>PLoS Pathogens</i> , 2011, 7, e1002286.	2.1	203
100	Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. <i>Journal of Infectious Diseases</i> , 2011, 204, 753-760.	1.9	125
101	Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2010, 7, 15.	0.7	186
102	Compartmentalization and Clonal Amplification of HIV-1 Variants in the Cerebrospinal Fluid during Primary Infection. <i>Journal of Virology</i> , 2010, 84, 2395-2407.	1.5	142
103	HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2010, 202, 1819-1825.	1.9	255
104	Compartmentalized Human Immunodeficiency Virus Type 1 Originates from Long-Lived Cells in Some Subjects with HIV-1-Associated Dementia. <i>PLoS Pathogens</i> , 2009, 5, e1000395.	2.1	132
105	Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection. <i>PLoS ONE</i> , 2009, 4, e6877.	1.1	77
106	Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 168-173.	0.9	96
107	Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 544-552.	0.9	52
108	Enfuvirtide Cerebrospinal Fluid (CSF) Pharmacokinetics and Potential use in Defining CSF HIV-1 Origin. <i>Antiviral Therapy</i> , 2008, 13, 369-374.	0.6	27

#	ARTICLE	IF	CITATIONS
109	Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2007, 196, 1779-1783.	1.9	164
110	Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 112-119.	2.1	45
111	Treatment Benefit on Cerebrospinal Fluid HIV RNA Levels in the Setting of Systemic Virological Suppression and Failure. <i>Journal of Infectious Diseases</i> , 2006, 194, 1686-1696.	1.9	83
112	Missense Mutations in the Rod Domain of the Lamin A/C Gene as Causes of Dilated Cardiomyopathy and Conduction-System Disease. <i>New England Journal of Medicine</i> , 1999, 341, 1715-1724.	13.9	1,195
113	Immunological, Cognitive and Psychiatric Outcomes after Initiating EFV- and DTG-based Antiretroviral Therapy during Acute HIV Infection. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	5